EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fragment-Based Approaches Identified Tecovirimat-Competitive Novel Drug Candidate for Targeting the F13 Protein of the Monkeypox Virus

Yasir Ali iD, Hina Imtiaz, Muhammad Mutaal Tahir, Fouzia Gul, Umair Ali Khan Saddozai, Ashfaq Ur Rehman iD, Zhi-Guang Ren, Saadullah Khattak iD, Xin-Ying Ji

Viruses · 2023

DOI: 10.3390/v15020570 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Yasir Ali und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Bioinformatics, Quaid-i-Azam University, Islamabad 45320, Pakistan. Hauptthemen laut MEDLINE: Monkeypox virus, Mpox, Monkeypox. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Kaifeng Science and Technology Development Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monkeypox is a serious public health issue in tropical and subtropical areas. Antivirals that target monkeypox proteins might lead to more effective and efficient therapy. The F13 protein is essential for the growth and maturation of the monkeypox virus. F13 inhibition might be a viable therapeutic target for monkeypox. The in silico fragment-based drug discovery method for developing antivirals may provide novel therapeutic options. In this study, we generated 800 compounds based on tecovirimat, an FDA-approved drug that is efficacious at nanomolar quantities against monkeypox. These compounds were evaluated to identify the most promising fragments based on binding affinity and pharmacological characteristics. The top hits from the chemical screening were docked into the active site of the F13 protein. Molecular dynamics simulations were performed on the top two probable new candidates from molecular docking. The ligand–enzyme interaction analysis revealed that the C2 ligand had lower binding free energy than the standard ligand tecovirimat. Water bridges, among other interactions, were shown to stabilize the C2 molecule. Conformational transitions and secondary structure changes in F13 protein upon C2 binding show more native three-dimensional folding of the protein. Prediction of pharmacological properties revealed that compound C2 may be promising as a drug candidate for monkeypox fever. However, additional in vitro and in vivo testing is required for validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Monkeypox virusMpox, MonkeypoxHumansLigandsMolecular Docking SimulationAntiviral AgentsBenzamidesIsoindoles

Stichwörter der Autor:innen

F13 proteinfragment-based drug designmolecular dynamics simulationmonkeypox virustecovirimat

Substanzen

LigandsAntiviral AgentsBenzamidesIsoindoles

Autor:innen und Institutionen

  • National Center for Bioinformatics, Quaid-i-Azam University, Islamabad 45320, Pakistan.
  • Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
  • Tehsil Headquarter Hospital Bhera, Sargodha, Punjab 40540, Pakistan.
  • District Headquarter Hospital Faisalabad, Punjab 38000, Pakistan.
  • Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, CA 2697-3900, USA.
  • The First Affiliated Hospital, Henan University, Kaifeng 475004, China.

ORCID-Profile: Yasir Ali, Ashfaq Ur Rehman, Saadullah Khattak

Förderung

  • National Natural Science Foundation of China
  • Kaifeng Science and Technology Development Plan

Zitieren

APA

Ali, Y., Imtiaz, H., Tahir, M. M., Gul, F., Saddozai, U. A. K., Ur Rehman, A., Ren, Z. G., Khattak, S., & Ji, X. Y. (2023). Fragment-Based Approaches Identified Tecovirimat-Competitive Novel Drug Candidate for Targeting the F13 Protein of the Monkeypox Virus. Viruses. https://doi.org/10.3390/v15020570

Vancouver

Ali Y, Imtiaz H, Tahir MM, Gul F, Saddozai UAK, Ur Rehman A, et al. Fragment-Based Approaches Identified Tecovirimat-Competitive Novel Drug Candidate for Targeting the F13 Protein of the Monkeypox Virus. Viruses. 2023. doi:10.3390/v15020570

BibTeX
@article{Ali2023,
  author = {Ali, Yasir and Imtiaz, Hina and Tahir, Muhammad Mutaal and Gul, Fouzia and Saddozai, Umair Ali Khan and Ur Rehman, Ashfaq and Ren, Zhi-Guang and Khattak, Saadullah and Ji, Xin-Ying},
  title = {Fragment-Based Approaches Identified Tecovirimat-Competitive Novel Drug Candidate for Targeting the F13 Protein of the Monkeypox Virus},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15020570}
}
Kostenlos starten →